<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 23-year-old man with severe idiopathic <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> was prepared for marrow transplantation by the administration of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CY) 50 mg/kg on each of 4 days </plain></SENT>
<SENT sid="1" pm="."><plain>He then received an intravenous infusion of 9.5 x 10(9) marrow cells from an <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-A matched and mixed leukocyte culture non-reactive sister </plain></SENT>
<SENT sid="2" pm="."><plain>The graft was successfully established as shown by cytogenetic studies but was rejected after approximately 4 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>In preparation for a second transplant he was given procarbazine 12.5 mg/kg and goat antihuman thymocyte globulin (ATG) 7 mg/kg administered on alternate days for a total of 4 doses of each agent </plain></SENT>
<SENT sid="4" pm="."><plain>At the end of this therapy his white blood cell count was noted to be going up and the second transplant was not carried out </plain></SENT>
<SENT sid="5" pm="."><plain>Complete hematologic recovery of host type marrow ensued and persists now 20 months later </plain></SENT>
<SENT sid="6" pm="."><plain>The various pathophysiologic mechanisms that may be involved are discussed </plain></SENT>
</text></document>